12,372 trials
Seasonal Influenza
Primary: Comparison of Antibody Responses of Investigational TIV to Control Vaccine in Terms of the Percentage of Subjects Achieving Seroconversion — 95; 94; 78; 87 Percentages
Pulmonary Hypertension
Primary: 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 16 — 38.9; -5.5 Meters — p=<0.0001
Meningococcal Disease · Meningococcal Meningitis
Primary: Percentage of Subjects With hSBA Titers ≥1:4 Against Meningococcal Strains, At 18 Months After Month-6 Vaccination in V72P10 Study, and in Naive Subjects. — 31; 40; 40…
Cystic Fibrosis · Burkholderia Infections
Primary: AUCave of Relative Change in FEV1 % Predicted From Baseline to Week 24 — 0.16; -0.75 percent change in FEV1% predicted — p=0.663
Meningococcal Disease · Meningococcal Meningitis · Typhoid
Primary: Geometric Mean Anti-typhoid Vi Antibody Concentrations — 6.37; 5.6; 134; 153 El.U/mL
Asthma
Primary: Forced Expiratory Volume in 1 Second (FEV1) - Post Dose — 2.09; 1.97; 2.12; 2.49 Liter — p=0.001
Dentine Hypersensitivity
Primary: Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Week 8 — -0.9; -0.5 Score on a scale — p=<0.0001
Anxiety Disorders · HIV Infections
Primary: Change From Randomization to End of Treatment in Scores on the Hamilton Anxiety Rating Scale (HAM-A) — 21.23 scores on an anxiety scale
Melanoma
Primary: Overall Survival (OS) — 11.17; 9.07 Months — p=0.0009
Meningococcal Disease · Meningococcal Meningitis · Hepatitis A
Primary: Geometric Mean antiHAV and antiHBV Concentrations (GMCs), 28 Days After Primary and Booster Vaccination — 48; 30; 786; 884 Concentrations (mIU/mL)
Bone Metastases
Primary: Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority) — 372; 315 Participants — p=<0.0001
Japanese Encephalitis
Primary: Long Term Immunogenicity of IC51 Vaccine 24 Months After the Primary Vaccination — 56; 7; 5 percentage of participants
Hypogonadism
Primary: Percentage of Participants Meeting Serum Total Testosterone Average Concentration (Cavg) Criteria at Day 90 — 77.5 percentage of participants
Vomiting · Cisplatin Adverse Reaction
Primary: Number of Patients With Complete Response During Chemotherapy Course 1 — 17; 26 participants — p=0.04
Reducing Time to Vaginal Delivery · Cervical Ripening · Induction of Labor
Primary: Time to Vaginal Delivery During the First Hospital Admission — 1292.00; 1968.50 minutes — p=<0.001